Vunakizumab
As of the edition of 20 October 2026, Vunakizumab is an antibody: in active development; acts on IL17A.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2025
- Kind
- Antibody
- Registered trials
- 19, 1 stopped early
- Disease areas
- Skin and connective tissue; Bones, joints and muscles; Immune system; Cancer; Heart and blood vessels; Lungs and airways
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| IL17A | Interleukin-17A | Q16552 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 6 | 3 | 1 | 0 |
| Phase 2 | 5 | 2 | 1 | 1 |
| Phase 3 | 5 | 1 | 3 | 0 |
| Phase 4 | 3 | 0 | 3 | 0 |
| All trials | 19 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Atridia | Lead sponsor of trials | 2016 to now |
| Jiangsu HengRui Medicine | Lead sponsor of trials | 2017 to now |